Darnatein

Darnatein is a South Korean biotechnology company focused on developing next-generation regenerative biologics for musculoskeletal and tissue repair. As a subsidiary of OSR Holdings, the company utilizes its proprietary Design-Augmented (DA) Biologics platform, which integrates synthetic biology and AI-enhanced protein engineering to create super-agonists that restore signaling balance in the body. Its lead candidate, DRT-101, is a chimeric BMP-7/Activin protein being developed as a disease-modifying osteoarthritis drug (DMOAD). The company's pipeline also includes DRT-102, a BMP-2 super-agonist currently in clinical development for spinal fusion applications.